HyQvia Ig infusion 10% regulatory update

FDA approved a BLA from Baxter for subcutaneous HyQvia Ig infusion 10% to treat primary immunodeficiency in adults. Baxter said it plans to launch HyQvia in the "coming weeks," but declined to disclose the drug's price. Baxter said HyQvia gives patients the option of monthly self-administration or administration by a professional, while current subcutaneous Ig products require weekly or bi-weekly treatment with multiple infusion sites per treatment. ...